PVLA

Company Overview — What Does PALVELLA THERAPEUTICS, INC. Do?

Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania. PALVELLA THERAPEUTICS, INC. (PVLA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Wes Kaupinen, headquartered in WAYNE, Pennsylvania. With a market capitalization of $1.7B, PVLA is one of the notable companies in the Healthcare sector.

PALVELLA THERAPEUTICS, INC. (PVLA) Stock Rating — Reduce (April 2026)

As of April 2026, PALVELLA THERAPEUTICS, INC. receives a Reduce rating with a composite score of 35.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PVLA ranks #2,678 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PALVELLA THERAPEUTICS, INC. ranks #359 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PVLA Stock Price and 52-Week Range

PALVELLA THERAPEUTICS, INC. (PVLA) currently trades at $127.12. The stock lost $3.08 (2.4%) in the most recent trading session. The 52-week high for PVLA is $151.18, which means the stock is currently trading -15.9% from its annual peak. The 52-week low is $18.23, putting the stock 597.5% above its annual trough. Recent trading volume was 178K shares, suggesting relatively thin trading activity.

Is PVLA Overvalued or Undervalued? — Valuation Analysis

PALVELLA THERAPEUTICS, INC. (PVLA) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 61.40x, versus the sector average of 2.75x. The price-to-sales ratio is 829.98x, compared to 1.66x for the average Healthcare stock.

At current multiples, PALVELLA THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PALVELLA THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

PALVELLA THERAPEUTICS, INC. (PVLA) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -127.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -60.1% versus the sector average of -33.1%.

The operating margin is -1335.9% (sector: -66.1%). Net profit margin stands at -1422.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PVLA Debt, Balance Sheet, and Financial Health

PALVELLA THERAPEUTICS, INC. has a debt-to-equity ratio of 113.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 5.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $64M.

PVLA has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for PALVELLA THERAPEUTICS, INC. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PALVELLA THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PALVELLA THERAPEUTICS, INC. reported revenue of $2M and earnings per share (EPS) of $-3.71. Net income for the quarter was $-36M. Gross margin was 0.0%. Operating income came in at $-32M.

In FY 2025, PALVELLA THERAPEUTICS, INC. reported revenue of $3M and earnings per share (EPS) of $-3.71. Net income for the quarter was $-42M. Operating income came in at $-39M.

In Q3 2025, PALVELLA THERAPEUTICS, INC. reported revenue of $628,000 and earnings per share (EPS) of $-1.03. Net income for the quarter was $-11M. Operating income came in at $-10M.

In Q2 2025, PALVELLA THERAPEUTICS, INC. reported revenue of $690,000 and earnings per share (EPS) of $-0.86. Net income for the quarter was $-9M. Operating income came in at $-9M.

Over the past 8 quarters, PALVELLA THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $0 to $2M. Investors analyzing PVLA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PVLA Dividend Yield and Income Analysis

PALVELLA THERAPEUTICS, INC. (PVLA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PVLA Momentum and Technical Analysis Profile

PALVELLA THERAPEUTICS, INC. (PVLA) has a momentum factor score of 76/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PVLA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PALVELLA THERAPEUTICS, INC. (PVLA) ranks #359 out of 838 stocks based on the Blank Capital composite score. This places PVLA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PVLA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PVLA vs S&P 500 (SPY) comparison to assess how PALVELLA THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

PVLA Next Earnings Date

No upcoming earnings date has been announced for PALVELLA THERAPEUTICS, INC. (PVLA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PVLA? — Investment Thesis Summary

The quantitative profile for PALVELLA THERAPEUTICS, INC. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Price momentum is positive at 76/100, suggesting the trend favors buyers. High volatility (stability score 36/100) increases portfolio risk.

In summary, PALVELLA THERAPEUTICS, INC. (PVLA) earns a Reduce rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PVLA stock.

Related Resources for PVLA Investors

Explore more research and tools: PVLA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PVLA head-to-head with peers: PVLA vs AZN, PVLA vs SLGL, PVLA vs VMD.